ArticleCardiovascular diabetology2018

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.

Fumika Shigiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.